| 論文種別 | 原著(症例報告除く) |
| 言語種別 | 英語 |
| 査読の有無 | その他(不明) |
| 表題 | Eribulin versus S-1 as fi rst or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a noninferiority, randomised, controlled, open-label, phase 3 trial |
| 掲載誌名 | 正式名：EClinicalMedicine ISSNコード：25895370 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 74,pp.102715 |
| 著者・共著者 | Takahashi, M; Kikawa, Y; Kashiwabara, K; Taira, N; Iwatani, T; Shimozuma, K; Ohtani, S; Yoshinami, T; Watanabe, J; Kashiwaba, M; Watanabe, K; Kitada, M; Sakaguchi, K; Tanabe, Y; Aihara, T; Mukai, H |
| 発行年月 | 2024/07 |
| DOI | 10.1016/j.eclinm.2024.102715 |
| PMID | 39109189 |